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Objective: The role of hypertension and its impact on
outcome in patients with acute coronary syndrome (ACS)
is still debated. This study aimed to compare the outcomes
of hypertensive and nonhypertensive ACS patients.
Methods: Using data of ACS patients enrolled in the
Acute Myocardial Infarction in Switzerland Plus Registry
from 1997 to 2013, characteristics at presentation and
outcomes in hospital and after 1 year were analyzed.
Hypertension was defined as previously diagnosed and
treated by a physician. The primary endpoint was
mortality. Data were analyzed using multiple logistic
regressions.
Results: Among 41771 ACS patients, 16 855 (40.4%)
were without and 24916 (59.6%) with preexisting
hypertension. Patients with preexisting hypertension had a
more favorable in-hospital outcome [odds ratio (OR) in-
hospital mortality 0.82, 95% confidence interval (CI)
0.73–0.93; P¼ 0.022]. The independent predictors of in-
hospital mortality for patients with preexisting
hypertension were age, Killip class greater than 2,
Charlson Comorbidity Index greater than 1, no
pretreatment with statins and lower admission systemic
blood pressure. Preexisting hypertension was not an
independent predictor of 1-year mortality in the
subgroup of patients (n¼7801) followed: OR 1.07, 95%
CI 0.78–1.47; P¼0.68. Independent predictors of
mortality 1 year after discharge for the 4796 patients with
preexisting hypertension were age, male sex and
comorbidities. Angiotensin-converting enzyme inhibitors or
angiotensin II receptor antagonists and statins prescribed
at discharge improved the outcomes.
Conclusion: Outcome of ACS patients with preexisting
hypertension was associated with an improved in-hospital
prognosis after adjustment for their higher baseline risk.
However, this effect was not long-lasting and does not
necessarily mean a causal relationship exists. Short-term
and long-term management of patients with hypertension
admitted with ACS could be further improved.
Keywords: acute coronary syndrome, hypertension,
therapy
Abbreviations: ACEI, angiotensin-converting enzyme
inhibitors; ACS, acute coronary syndrome; AMI, acute
myocardial infarction; AMIS, Acute Myocardial Infarction in
Switzerland; ARBs, angiotensin II receptor antagonists; BP,
blood pressure; CCI, Charlson Comorbidity Index; CI,
confidence interval; LBBB, left bundle branch block;
MACCEs, major adverse cardiac or cardiovascular events;
MI, myocardial infarction; NSTEMI, non-ST-segment
elevation myocardial infarction; OR, odds ratio; SD,
standard deviation; STEMI, ST-segment elevation
myocardial infarction
INTRODUCTION
H
ypertension is an established risk factor of athero-
sclerosis and its sequelae [1]. However, the impact
of preexisting hypertension on prognosis in
patients with acute coronary syndrome (ACS) is less clear
[2,3]. Some studies suggested that preexisting hypertension
and elevated blood pressure (BP) at admission contribute to
a worse prognosis [4–6]. Other studies found better in-
hospital outcomes in hypertensive patients with ACS than in
age-matched and sex-matched normotensive individuals,
perhaps because of a less severe extension of the infarction
area or other unknown pathophysiologic mechanisms [7]. A
previous study suggested that ACS mortality is strongly
related to admission BP with a J-shaped or U-shaped curve
association, with the lowest adverse event rates in the SBP
range of 130–140mmHg and DBP range of 80–90mmHg
[8]. A large study showed that elevated admission SBP in
patients with ST-segment elevation myocardial infarction
(STEMI) was not associated with worse outcomes [9]. We
assumed that preexisting hypertension might be protective
in ACS patients in the short term despite its clearly
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established role in increasing the long-term risk for coron-
ary artery disease. Similar paradoxes have been previously
described for smokers [10] as well as for patients with
obesity [11].
Previous studies evaluating the role of hypertension in
ACS had their own limitations. Results from randomized
trials or retrospective cohorts may be subject to selection
bias. Some of the studies were not powered to investigate
the question in detail or did not assess important variables
such as admission BP or medications. Therefore, we aimed
to evaluate the impact of preexisting hypertension in ACS
patients on in-hospital and 1-year outcomes using the large,
comprehensive and prospective Swiss Acute Myocardial
Infarction in Switzerland (AMIS) Plus Registry [12–15].
METHODS
The Acute Myocardial Infarction in Switzerland
Plus Registry
The AMIS Plus Registry is an ongoing nationwide prospec-
tive registry of patients admitted with ACS to hospitals in
Switzerland [11,16]. From 106 hospitals treating ACS in
Switzerland, 82 hospitals temporarily or continuously
enrolled patients in the AMIS Plus Registry since it was
founded in 1997. Participating centers range from com-
munity institutions to large tertiary facilities and provide
blinded data for each patient through standardized internet-
based or paper-based questionnaires. Participating centers
are strongly encouraged to enroll all patients fulfilling the
inclusion criteria to avoid selection bias. Hospital data are
provided and completed by the treating physician or a
trained study nurse. All data are checked for completeness,
plausibility and consistency by the AMIS Plus Data Center
(Epidemiology, Biostatistics and Prevention Institute, Uni-
versity of Zurich, Switzerland).
The data center queries the treating physicians or study
nurses in case of incomplete, implausible or inconsistent
data. To control and assure data quality, for the last 5 years
external auditing has been additionally performed regularly
in randomly selected hospitals with randomly selected
patients. The auditing objective in AMIS Plus participating
hospitals was to review the selected data items per source
data verification in order to assess the level of compliance
with the protocol and guidelines. The grading of findings
was performed according to the ‘procedure for reporting of
good-clinical-practice compliance inspections’ requested
by the European Medicines Agency. The AMIS Plus Registry
was approved by the Swiss Supra-Regional Ethics Commit-
tee for Clinical Studies, the Swiss Board for Data Security
and the Cantonal Ethics Commissions. The AMIS Plus
project is supported by the Swiss Societies of Cardiology,
Internal Medicine and Intensive Care Medicine.
Patient selection
The present analysis included all ACS patients enrolled in
AMIS Plus between January 1997 and December 2013. The
ACS definition included patients with acute myocardial
infarction (AMI) and patients with unstable angina. AMI
was defined according to the universal definition of myo-
cardial infarction (MI) by characteristic symptoms and ECG
changes and cardiac marker elevation (either creatine
kinase Muscle-Brain fraction at least twice the upper limit
of normal or troponin I or T above individual hospital cutoff
levels for MI) [17]. Patients included in this analysis were
categorized as having STEMI or non-STEMI (NSTEMI)
based on the initial ECG findings. Classification of STEMI
included evidence of AMI as above and ST-segment
elevation and new left bundle branch block (LBBB) on
the initial ECG. NSTEMI included patients with ischemic
symptoms, ST-segment depression or T-wave abnormal-
ities in the absence of ST elevation on the initial ECG [18].
Unstable angina was diagnosed if symptoms or ECG
changes were compatible with ACS and cardiac marker
levels remained lower than cutoff or normal levels.
Baseline evaluation at hospital admission
All patients were extensively evaluated at hospital admis-
sion. The usual evaluation included taking the patient’s
history of preexisting comorbidities, assessing the medi-
cations, measuring BP with usual devices, measuring
cardiac markers as well as recording an ECG. In the context
of this study, preexisting hypertension was assumed if
history of hypertension was known and previously treated
according to the guidelines [19–21]. To measure the extent
of comorbidities, we used the weighted Charlson Comor-
bidity Index (CCI) [22,23]. Patients were considered obese if
the BMI was at least 30 kg/m2 and as smokers if the patient
was a current smoker at the time of hospital admission.
Follow-up and endpoints
The AMIS Plus Registry assesses in-hospital outcomes in all
patients, including mortality and the occurrence of major
adverse cardiac or cardiovascular events (MACCEs). Since
2006, the registry also assesses the outcomes 12 months
after hospital discharge. For the present analysis, the
primary endpoint was in-hospital and 1-year mortality.
The secondary composite endpoint MACCE was analyzed
and included re-infarction, stroke and death in hospital.
Statistical analysis
First, baseline characteristics were descriptively analyzed
according to the hypertension status and then in-hospital
and 1-year outcomes. As hypertension may be associated
with age, sex, comorbidities and other circumstances, we
performed the multiple logistic regression models using
in-hospital and 1-year mortality as the dependent variable.
This first model, which included all ACS patients, was
adjusted for the following independent variables: preexist-
ing hypertension, age, sex, Killip class greater than 2, CCI
greater than 1 and presence of a STEMI. To control the
impact of ACS type on in-hospital mortality, this model was
repeated separately for patients with STEMI and patients
with NSTEMI or unstable angina. To control the impact of
immediate therapy on in-hospital mortality of all ACS
patients, the model was repeated to additionally include
guideline recommended therapy, such as one of the
P2Y12 blockers (clopidogrel, prasugrel or ticagrelor), beta-
blockers, angiotensin-converting enzyme inhibitors (ACEIs)
or angiotensin II receptor antagonists (ARBs) and statins.
We were ultimately interested in factors potentially
explaining the association of preexisting hypertension with
mortality. Therefore, the secondmultiple logistic regression
Hypertension in acute coronary syndrome
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model was performed including only the subgroup of
patients with hypertension again using in-hospital and 1-
year mortality as the dependent variable. The following
independent variables were included in the model: age,
sex, Killip class greater than 2, CCI greater than 1, presence
of a STEMI, admission SBP, and drugs used regularly prior
to the current event as a monotherapy or combined with
diuretics (i.e., ACEI, ARB, beta-blockers, and Ca-channel
blockers) and statins. To analyze the data according to BP
at admission and 1-year mortality, additional logistic
regressions were performed using BP values of 140, 150
and 160mmHg as dichotomous variables adjusted for age,
sex, Killip class greater than 2, CCI greater than 1 and added
the maximum creatine kinase value as a measurement of
the infarct burden. The results are presented as percentages
for categorical variables and analyzed using the nonpara-
metric Pearson x2 test or Fisher’s exact test as appropriate.
Continuous normally distributed variables are expressed as
meansone standard deviation (SD) and compared using
the Student’s two-tailed unpaired t-test. Continuous non-
normally distributed variables are expressed as medians
and interquartile ranges, and analyzed using the Mann–
Whitney U test. Results of logistic regression are reported as
odds ratios (ORs) with 95% confidence interval (CI). A
probability value of P less than 0.05 was considered sig-
nificant. All analyses were performed using IBM SPSS
Statistics (version 22; SPSS Inc, Chicago, Illinois, USA).
RESULTS
Study population
Between January 1997 and December 2013, 43 912 patients
with ACS from 82 Swiss hospitals were enrolled in the AMIS
Plus Registry. There was no documentation of history of
hypertension for 2141 (4.9%) patients; therefore, these
patients were excluded from the analysis. Of the 41 771
included patients, 16 855 (40.4%) had no preexisting
hypertension, whereas 24 916 (59.6%) had previous hyper-
tension. The baseline details of patients are described in
Table 1.
Patients with preexisting hypertension were somewhat
older and less often experienced a STEMI compared with
patients without preexisting hypertension. The classical
cardiovascular risk factors and other comorbidities were
more frequent in patients with preexisting hypertension.
These patients were also less likely to be chosen for
immediate mechanical revascularization.
In-hospital outcome
Overall complication rates and crude in-hospital mortality
were higher in hypertensive patients (Fig. 1).
TABLE 1. Baseline characteristics and immediate drug therapy of acute coronary syndrome patients according to hypertension history
(n¼41771)
Patients with preexisting
hypertension (n¼24916)
Patients without preexisting
hypertension (n¼16855) P
Female (%) 31.3 21.2 <0.001
Age in years [mean (SD)] 69.3 (12.2) 61.6 (13.2) <0.001
STEMI (%) 51.7 62.7 <0.001
Resuscitation prior admission (%) 979/24488 (4.0) 815/16643 (4.9) <0.001
Delay h:min (symptom to admission) median (IQR) 4:05 (2:00, 11:40) 3:30 (1:45, 10:00) <0.001
Admission SBP (mmHg), mean (SD) 141 (29) 131 (25) <0.001
Admission DBP (mmHg), mean (SD) 81 (18) 79 (16) <0.001
Heart rate (beats/min), mean (SD) 80 (21) 77 (20) <0.001
Killip class >2 (%) 1906/24472 (7.8) 876/16620 (5.3) <0.001
Diabetes mellitus (%) 6499/24210 (26.8) 1801/16698 (10.8) <0.001
Dyslipidemia (%) 14372/22388 (64.2) 7257/15757 (46.1) <0.001
Current smoker (%) 6875/22671 (30.3) 7778/16058 (48.4) <0.001
Obese (BMI >30) (%) 5087/20576 (24.7) 1916/13884 (13.8) <0.001
Charlson Comorbidity Index >1 (CCI >1) (%) 6170/19497 (31.6) 1509/12128 (12.4) <0.001
Immediate therapy
Percutaneous coronary intervention (%) 15472/21684 (71.4) 11292/14024 (80.5) <0.001
P2Y12 blocker (%) 15897/24499 (64.9) 10967/16718 (65.6) 0.14
Beta-blocker (%) 16247/24097 (67.4) 10695/16389 (65.3) <0.001
ACEI/ARB antagonist (%) 13373/24023 (55.7) 6750/16294 (41.4) <0.001
Statin (%) 14608/19927 (73.3) 9640/12439 (77.5) <0.001
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; P2Y12 blockers, clopidogrel, prasugrel or ticagrelor; STEMI, ST-segment elevation myocardial
infarction.
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FIGURE 1 Complications and crude in-hospital mortality of acute coronary syn-
drome patients according to hypertension history (n¼41771).
Erne et al.
862 www.jhypertension.com Volume 33  Number 4  April 2015
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
However, after adjustment for covariates, patients with
preexisting hypertension had better in-hospital mortality
(OR 0.82, 95% CI 0.73–0.93; P¼ 0.002; Fig. 2). ACS patients
with preexisting hypertension also had better outcomes
regarding the composite endpoint of MACCEs (OR 0.85,
95% CI 0.76–0.96; P¼ 0.006).
Even after adjustment for immediate antiplatelet therapy
and percutaneous coronary intervention (PCI), a history
of hypertension remained significant (OR 0.86, 95% CI
076–0.97; P¼ 0.022). Logistic models performed separately
for patients with NSTEMI/unstable angina and those with
STEMI showed that NSTEMI/unstable angina patients with
preexisting hypertension had significantly improved in-
hospital mortality (OR 0.67, 95% CI 0.55–0.83; P< 0.001),
whereas no significant improvement was seen in STEMI
patients (OR 0.91, 95% CI 0.78–1.07; P¼ 0.26).
The relation between admission SBP and prognosis
followed a J-shaped curve associated with increased
mortality below the range of 130–140mmHg for ACS
patients with preexisting hypertension (P¼ 0.002) and
below the range of 120–130mmHg for patients without
previous hypertension (P¼ 0.004; Fig. 3). Adjusted OR of
1-year mortality for BP above 140mmHg at admission for
hypertensive patients was 0.57 (95% CI 0.42–0.77;
P< 0.001), for BP above 150mmHg 0.62 (95% CI 0.45–
0.86; P< 0.001) and for BP above 170mmHg, the OR was
0.61 (95% CI 0.49–0.96; P¼ 0.042).
In the subgroup of patients with preexisting hyper-
tension, the following baseline characteristics were
independent predictors of increased in-hospital mortality:
higher age, presence of a STEMI, higher Killip class, increas-
ing numbers of comorbidities, no pretreatment with statins
and lower admission SBP. Pretreatment with ACEI, ARB and
beta-blockers or calcium-channel blockers showed no
effect on in-hospital mortality (Table 2). Similar predictors
were found for patients without preexisting hypertension,
but the presence of a STEMI was no longer significantly
associated with the endpoint (Table 2).
Outcome 1 year after discharge
We carried out a follow-up of 7801 patients 12 months after
hospitalization. Patients with preexisting hypertension had
worse unadjusted outcomes (Fig. 4). The percentage of ACS
patients who underwent any re-intervention was not sig-
nificantly different between the patients with and those
without preexisting hypertension (P¼ 0.078), but stroke
(P¼ 0.020), reinfarction (P< 0.001) and crude mortality
were higher in patients with hypertension (P< 0.001)
during the follow-up period of 1 year (Fig. 4).
However, after adjustment for covariates, history of
hypertensionwas not an independent predictor of mortality
after 1 year (OR 1.07, 95% CI 0.78–1.47; P¼ 0.68; Fig. 5).
The most decisive factors of mortality were comorbidities
(OR 4.44, 95% CI 3.36–5.88; P< 0.001) and patient age (OR
for each additional year 1.08, 95% CI 1.06–1.09; P< 0.001).
For 4796 ACS patients with preexisting hypertension,
age, comorbidities and male sex were associated with
worse outcomes 1 year after discharge. In 3005 patients
without preexisting hypertension, independent predictors
of follow-up mortality were similar (Table 3).
With regard to prescribed antihypertensive drugs at
discharge as monotherapy or only combined with diuretics,
patients who received ACEI/ARB had lower mortality (OR
0.45, 95% CI 0.30–0.78; P¼ 0.004). Other antihypertensives
had no effect on mortality. However, statins prescribed at
discharge improved 1-year outcome (OR 0.48, 95% CI 0.32–
0.71; P¼ 0.001).
DISCUSSION
To examine the impact of preexisting hypertension on
outcome in patients admitted for ACS, we analyzed the
data from the large prospective national AMIS Plus Registry.
Unadjusted in-hospital mortality was higher in hypertensive
patients. After correction for age, sex, Killip class and
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FIGURE 2 Independent predictors of in-hospital mortality. 95% CI, 95% confi-
dence interval; CCI >1, Charlson Comorbidity Index greater than 1; OR, odds
ratio; STEMI, ST-segment elevation myocardial infarction.
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comorbidities, however, in-hospital mortality in previously
known hypertensive ACS patients was lower. The higher
BP on admission was prognostically favorable for both
hypertensive and nonhypertensive patient groups, which
is in accordance with the results from the ‘PROVE-IT-TIMI’
22 trial [8]. The relation between admission SBP and prog-
nosis in this study followed the J-shaped curve associated
with increased mortality below the range of 130–
140mmHg for ACS patients with preexisting hypertension
and below the range of 120–130mmHg for patients without
previous hypertension. From the additional analysis of BP
at admission and 1-year outcome, we could conclude that
the initial BP measurement does not seem to have an effect
on nonhypertensive patients. However, patients with pre-
existing hypertension did profit from a SBP above 140 and
up to 170mmHg. Thus, our data suggest that the goal of
initial BP management in patients with prehypertension
admitted with ACS should not be to lower BP below 160–
170mmHg. However, these results were based on a single
measurement of BP at admission in all ACS patients regard-
less of delay, transfer, measurement utilities, medication,
comorbidities or start of therapy. We do see the need to
include follow-up BP recordings and we did not consider
DBP measurements which are difficult to measure in the
emergency room.
The prehospital and hospital delays may have a great
impact on the outcome of patients hospitalized for STEMI as
well as NSTEMI. NSTEMI patients with preexisting hyper-
tension had a somewhat shorter delay between symptom
onset and admission compared with those with STEMI.
However, these patients underwent PCI with longer delays
than patients without preexisting hypertension (data not
shown). This excess delay, which may adversely affect
prognosis, can be explained by higher age, comorbidity
and female sex as observed in former analyses [14,22,24].
Regarding cardiovascular risk factors in hypertensive
patients such as hypercholesteronemia, smoking and over-
weight, the results of our study are similar to the results
from the large cohort survey from Italy [25], except for
diabetes mellitus, which in our hypertensive patient group
was double the incidence than their population of hyper-
tensive patients.
Patient’s age, the extent of reduced left ventricular func-
tion as documented by Killip classes, comorbidities, STEMI
and lower admission BP were associated with worse in-
hospital outcomes of patients with hypertension hospital-
ized for ACS.
The ‘protective’ effect of hypertension in ACS patients is
difficult to explain. Pretreatment with potentially cardio-
protective antihypertensive drugs had no apparent effect
TABLE 2. Independent predictors of in-hospital mortality
Patients with preexisting
hypertension
Patients without preexisting
hypertension
OR 95% CI P OR 95% CI P
Age per additional year 1.07 1.06–1.08 <0.001 1.08 1.06–1.09 <0.001
Female sex 1.16 0.96–1.41 0.13 1.20 0.93–1.55 0.17
STEMI 1.45 1.19–1.75 <0.001 1.09 0.85–1.40 0.49
Killip class >2 4.62 3.69–5.78 <0.001 7.73 5.85–10.2 <0.001
Charlson Comorbidity Index >1 2.09 1.72–2.53 <0.001 1.71 1.29–0.26 <0.001
Admission SBP (per mmHg) 0.977 0.974–0.980 <0.001 0.973 0.968–0.977 <0.001
Pretreatment drugs as monotherapy or in combination with diuretics
ACE/ARB antagonist mono or with diuretics 0.85 0.68–1.08 0.19 1.14 0.68–1.91 0.62
Beta-blocker mono or with diuretics 1.04 0.80–1.34 0.79 0.72 0.46–1.14 0.17
Calcium-channel blocker mono or with diuretics 1.16 0.83–1.62 0.38 0.99 0.36–2.74 0.98
Statin 0.73 0.58–0.91 0.006 0.77 0.53–1.12 0.17
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; CCI >1, Charlson Comorbidity Index.
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FIGURE 4 Outcome 1 year after the discharge of acute coronary syndrome
patients according to preexisting hypertension (n¼7801).
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on mortality in our study. Analysis of pretreatment with
beta-blockers, calcium antagonists, ACEI, ARB or diuretics
in monotherapy or combination therapy showed no effects
on in-hospital mortality. We previously saw that pretreat-
ment of beta-blockers and particularly immediate treatment
after admission in patients with ACS had a slight protective
effect on in-hospital outcome [26], regardless of the history
of hypertension. In the subgroup of patients who con-
sented, we found no difference for adjusted 1-year mortality
in hypertensive versus nonhypertensive patients. The long-
term adverse effects of hypertension may therefore be
responsible for the vanishing short-term advantages in
hypertensive ACS patients. Not surprisingly, prescription
of an ACEI or ARB at discharge resulted in lower 1-year
mortality in these patients. A similar favorable effect was
demonstrated in the prescription of statins. These obser-
vations underline the utmost importance of consequent
secondary prevention after ACS especially in hypertensive
patients, who to some extent are undertreated as shown in
our analysis. This is in accordance with the large studies
from Italy. The study from Lombardia with an extremely
large number of hypertensive patients on real-world drug
utilization patterns showed that the discontinuation of the
initial single antihypertensive drug treatment is common,
but this is less the case with ARB medication, whereas
switching to another monotherapy or to combination treat-
ment occurred at much lower rates [27]. Another large
cohort survey that included over 52 000 patients showed
that there is poor persistence of BP control: only 22% of
hypertensive patients had optimal to high-normal BP [25].
Both these large population studies along with our study of
hypertensive patients hospitalized for ACS support the
need for more effective and comprehensive management
of patients with hypertension.
Limitations
Our study should be interpreted in the context of the
following limitations. First, the weakness of AMIS Plus is
common to all registries, the study is observational in nature
and participation is voluntary depending on the staff avail-
ability and motivation. However, the number of hospitals in
this study is extremely high and reflects the treatment
strategy in Switzerland. The quality of data is checked by
external audits. Quality control and benchmarking is the
task of every hospital, but this is not reflected in the
provision of resources, staff or financial support and no
group is fighting to close this gap. For this reason, the
registry is dependent on the financial support of sponsors
and donators, who do not play any role in data acquisition,
analysis or interpretation of the results.
Furthermore, we are aware that the treating physician is
using the current guidelines for the documentation of
elevated BP which changes regularly, and it was unknown
how long the history of hypertension existed. The BP value
used for this study is admission BP and the BP trends during
hospitalization were not documented. Furthermore, we
performed analyses based on SBP only. Although regular
medication is documented, there were no data on the
duration or compliance to treatment before the acute event.
However, the huge number of patients included enabled
assessment of the different aspects of hypertension on ACS
outcomes and evaluation of which factors were associated
with worse outcomes in hypertensive ACS patients.
Conclusion
ACS patients with hypertension are older, sicker and
present with more cardiovascular risk factors and comor-
bidities compared with those without hypertension.
Despite a higher risk profile, hypertensive patients para-
doxically underwent less frequently invasive revasculari-
zation. History of hypertension itself was nevertheless
associated with a more favorable in-hospital prognosis.
This effect vanished within 1 year after discharge.
Prescription of ACI and ARB as well as statins improved
long-term outcome. Short-term and long-termmanagement
of patients with hypertension admitted with ACS can be
further improved.
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